Valuation: Pharmena S.A.

Market Cap 3.34Cr 84.68L 76L 70.17L 63.64L 1.19Cr 80Cr 1.2Cr 8.41Cr 42Cr 3.18Cr 3.11Cr 133.69Cr P/E 2024
-33.8x
P/E 2025 -10.4x
Enterprise Value 3.34Cr 84.7L 76.02L 70.19L 63.65L 1.19Cr 80Cr 1.2Cr 8.42Cr 42Cr 3.18Cr 3.11Cr 133.73Cr EV / Sales 2024
154x
EV / Sales 2025 18.4x
Free-Float
29.7%
Yield 2024 *
-
Yield 2025 -
1 week+0.33%
Current month-1.96%
1 month-2.91%
3 months-3.23%
6 months-12.28%
Current year+15.38%
1 week 2.9
Extreme 2.9
3
1 month 2.9
Extreme 2.9
3.3
Current year 2.56
Extreme 2.56
4.32
1 year 2.5
Extreme 2.5
4.32
3 years 2.5
Extreme 2.5
9.18
5 years 2.5
Extreme 2.5
10.4
10 years 2.5
Extreme 2.5
33.48
Manager TitleAgeSince
Chief Executive Officer - 12/11/2002
Chief Tech/Sci/R&D Officer - 01/04/2008
Director TitleAgeSince
Director/Board Member 62 -
Director/Board Member 63 -
Director/Board Member 58 -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.33%-10.45%-51.30% 84.68L
-0.43%-0.06%+4.94%+8.20% 37TCr
-1.40%+6.47%+14.49%+10.13% 26TCr
-0.62%-0.22%-6.84%+13.82% 14TCr
-1.00%-2.51%+18.42%+28.39% 7.35TCr
-3.09%+5.71%+32.43% - 5.21TCr
-2.39%-4.17%-28.99%-28.47% 4.5TCr
-0.43%+2.10%+7.85%-12.99% 3.92TCr
-0.36%+0.78%+28.85%+6.70% 3.73TCr
-0.48%+0.71%-9.55%-6.64% 3.63TCr
Average -0.97%+1.14%+5.12%-3.57% 10.48TCr
Weighted average by Cap. -0.91%+1.68%+7.00%+7.89%

Financials

2024 2025
Net sales 3L 67.92T 60.96T 56.28T 51.04T 95.39T 64.51L 96.57T 7L 33.81L 3L 2L 1.07Cr 15.77L 4L 4L 3L 3L 6L 3.8Cr 6L 39.71L 1.99Cr 15L 14.68L 6.31Cr
Net income -12.62L -3L -3L -3L -2L -4L -3.04Cr -5L -31.78L -1.59Cr -12.01L -11.75L -5.05Cr -27.69L -7L -6L -6L -5L -10L -6.67Cr -10L -69.72L -3.49Cr -26.34L -25.78L -11Cr
Net Debt -15.01L -4L -3L -3L -3L -5L -3.61Cr -5L -37.79L -1.89Cr -14.28L -13.97L -6.01Cr 9T 2.28T 2.05T 1.89T 1.71T 3.2T 2L 3.24T 22.66T 1L 8.56T 8.38T 4L
Projected Income Statement - Annual - Pharmena S.A.
Logo Pharmena S.A.
Pharmena SA is a Poland-based pharmaceutical and life science company specializing in the research, development, and commercialization of products and technologies derived from scientific research, particularly in the areas of healthy aging, bioscience, and topical technologies. The Company is structured around research and development activities focused on the biological and therapeutic potential of 1-methylnicotinamide (1-MNA), a naturally occurring metabolite of niacin, and develops dietary supplements, health-related products, and drug candidates based on this technology. The Company's core activity centers on the application of 1-MNA technology, including products marketed under the Endotelio and Menavitin product lines. The Company conducts research in cooperation with academic institutions and research centers and supports its activities through patent protection and commercialization of developed technologies in domestic and international markets.
Employees
7
Date Price Change Volume
27/26/27 PLN 3.000 0.00% 300
26/26/26 PLN 3.000 +0.33% 877
23/26/23 PLN 2.990 0.00% 1,110
22/26/22 PLN 2.990 0.00% 349
21/26/21 PLN 2.990 0.00% 37